TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Analyst Ratings
USA - NASDAQ:TNXP - US8902608392 - Common Stock
20.35 USD
+0.86 (+4.41%)
20.58 USD
+0.23 (+1.13%)
ChartMill assigns a Buy % Consensus number of 83% to TNXP. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 69.02. This target is 239.16% above the current price.
TNXP was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about TNXP.
In the previous month the buy percentage consensus was at a similar level.
TNXP was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-03-20 | Noble Capital Markets | Reiterate | Outperform -> Outperform |
| 2024-07-22 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2024-02-28 | Dawson James | Initiate | Buy |
| 2023-08-01 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-06-02 | Alliance Global Partners | Maintains | Buy -> Buy |
| 2023-01-12 | Alliance Global Partners | Reiterate | Buy |
| 2022-04-18 | Noble Capital Markets | Initiate | Outperform |
TONIX PHARMACEUTICALS HOLDIN / TNXP FAQ
What is the price target for TNXP stock?
8 analysts have analysed TNXP and the average price target is 69.02 USD. This implies a price increase of 239.16% is expected in the next year compared to the current price of 20.35.
Can you provide the consensus rating for TONIX PHARMACEUTICALS HOLDIN stock?
The consensus rating for TONIX PHARMACEUTICALS HOLDIN (TNXP) is 82.5 / 100 . This indicates that analysts generally have a positive outlook on the stock.